Nyxoah SA (NYXH) Stock Forecast & Price Target

Nyxoah SA reported Q3 revenues of €2.0 million, marking a significant year-over-year increase of 56% and a quarter-over-quarter increase of 47%, aligning with both internal estimates and market expectations. The upcoming potential for repeat orders starting in 1Q26, coupled with favorable reimbursement trends from Medicare and major commercial payors, underscores the company's solid foundation for growth and commercial success. Additionally, with a €77 million financing boost and an expanded sales force in the U.S., Nyxoah is well-positioned to capitalize on its Genio system’s momentum, projecting substantial net revenue increases in early 2026.

Nyxoah SA reported a net loss per share of -€0.63, which was worse than both the internal model's estimate of -€0.54 and the wider market's expectation of -€0.59, signaling underlying financial challenges. Additionally, the company experienced a gross margin of 60.5%, falling short of the projected 65.0%, while operating expenses of €25.6 million exceeded expectations of €21.8 million, indicating potential inefficiencies in cost management. Furthermore, the company faces significant risks related to standard adoption processes, the necessity for additional capital in a cash-burn-intensive environment, and regulatory hurdles, all of which contribute to a recalibration of future revenue projections for FY 2026 and FY 2027.